个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Wang, K.[1] * ; Sun, H.[2] ; Bai, X.[3] ; Huang, Z-Y.[4] ; Song, T.[5] ; Chen, M.[6] ; Kuang, M.[7] ; Xiang, B.[8] ; Zeng, Y.[9] ; Liu, L-X.[10] ; Li, D.[11] ; Chen, Y.[12] ; Cai, J.[13] ; Xing, B.[14] ; Peng, T.[15] ; Zhang, X.[1] ; Zhu, X.[2] ; Zhou, J.[2] ; Fan, J.[2] ; Shen, F.[1] ;
单位： [1]Shanghai Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai, Peoples R China [2]Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China [3]Zhejiang Univ, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Med Sch, Hangzhou, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Liver Canc Ctr, Wuhan, Peoples R China [5]TMUCIH Tianjin Med Univ, Canc Inst & Hosp, Liver Canc Ctr, Tianjin, Peoples R China [6]Sun Yat Sen Univ, Liver Tumor Surg Dept, Ctr Canc, Guangzhou, Peoples R China [7]Sun Yat Sen Univ, Affiliated Hosp 1, Liver Canc Ctr, Guangzhou, Peoples R China [8]Guangxi Med Univ, Affiliated Tumor Hosp, Liver Canc Ctr, Guangxi, Peoples R China [9]Fujian Med Univ, Mengchao Hepatobiliary Hosp, Liver Tumor Surg Dept, Fuzhou, Peoples R China [10]Anhui Prov Hosp, Affiliated Hosp USTC 1, Liver Tumor Surg Dept, Hefei, Peoples R China [11]Peoples Hosp Zhengzhou, Liver Tumor Surg Dept, Zhengzhou, Peoples R China [12]Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Liver Canc Ctr, Shanghai, Peoples R China [13]Chinese Acad Med Sci, Canc Hosp, Liver Canc Ctr, Beijing, Peoples R China [14]Peking Univ, Hepatopancreatobiliary Surg Dept, Canc Hosp & Inst, Beijing, Peoples R China [15]Guangxi Med Univ, Affiliated Hosp 1, Hepatopancreatobiliary Surg Dept 1, Nanning, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.304
ISSN：
基金：
Shanghai Roche Pharmaceuticals Ltd., China
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Shanghai Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Wang K.,Sun H.,Bai X.,et al.Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab[J].ANNALS OF ONCOLOGY.2023,34:S1541-S1541.doi:10.1016/j.annonc.2023.10.304.
APA：
Wang, K.,Sun, H.,Bai, X.,Huang, Z-Y.,Song, T....&Shen, F..(2023).Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab.ANNALS OF ONCOLOGY,34,
MLA：
Wang, K.,et al."Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab".ANNALS OF ONCOLOGY 34.(2023):S1541-S1541

资源点击量：622 今日访问量：0 总访问量：452 更新日期：2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）